• Home
  • BioDuro-Sundia

BioDuro-Sundia

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product.  The company is the industry’s third largest, with operations in China and the US—featuring more than 2,400 employees and 11 global sites.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and un...

Read more Show less
Certifications
  • GMP
    GMP
  • ISO
    ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • US
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Contract Service
View company profile
Contact info
  • Website
  • 11011 Torreyana Rd., CA 92121, San Diego, United States
Show contact info Hide contact info
Meet us at

CPHI Barcelona 2023

Fira Barcelona Gran Via, Spain
24-26 October 2023
View Exhibitor Profile

Products from BioDuro-Sundia (5)

  • Drug Product Manufacturing

    Product Drug Product Manufacturing

    BioDuro-Sundia's Drug Product manufacturing services support clinical and commercial scale GMP production for a comprehensive range of oral solid dosage forms, including: solid, liquid, and semi solid dosage forms. This includes fully-audited manufacturing facilities (FDA and other regulators) with excepti...
  • Drug Substance

    Product Drug Substance

    BioDuro-Sundia’s Drug Substance manufacturing services support production of small molecule APIs, RSMs and intermediates--both GMP and non-GMP .  We provide a full range of production scale, supporting all stages of drug substance development through IND submission.  Fully integrated CMC ser...
  • Process Development

    Product Process Development

    BioDuro-Sundia’s process development services support drug substance production,  providing an efficient path to manufacture API or intermediates. Our extensive services support production of API for GLP toxicology studies, IND-enabling studies, clinical studies, and commercialization efforts. qq...
  • Formulation Development

    Product Formulation Development

    BioDuro-Sundia holds more than 25 years of experience formulating poor solubility and  poor permeability drugs for the clinical studies. Our comprehensive suite of advanced formulation technologies and extensive scientific know-how supports >95% of marketed dosage form...
  • Analytical Development

    Product Analytical Development

    BioDuro-Sundia’s Analytical Testing team offers high quality analytical services including method development and validation, qualification of reference standards, testing and release studies, stability studies, and CMC dossier preparation services. ...

BioDuro-Sundia Resources (3)

  • Drug Product - Development & Manufacturing

    Brochure Drug Product - Development & Manufacturing

    BioDuro-Sundia provides clinical development and commercial manufacturing of drug product—specializing in oral solid dosage forms and poorly soluble APIs. Our drug product services platform combines comprehensive pre-formulation assessment with advanced formulation technologies and robust GMP manufacturing capability.
  • Company Video - Integrated Drug Discovery, Development and Manufacturing at BioDuro-Sundia

    Video Company Video - Integrated Drug Discovery, Development and Manufacturing at BioDuro-Sundia

    BioDuro-Sundia is your partner for accelerating drug discovery, development and manufacturing--from molecule to market. Find out more at http://www.bioduro-sundia.com. 
  • Webinar - Protein Degraders

    Webinar Webinar - Protein Degraders

    Since 2015 the field of targeted protein degradation has rapidly emerged, offering opportunities for novel pharmacological interventions in ways impossible to achieve with traditional small molecule inhibitors. This webinar focuses on cutting-edge drug discovery using protein degraders, such as PROTACS, in diverse therapeutic areas. Attendees can expect to learn about recent strategies toward development of orally bioavailable protein degrader drug candidates—PROTACs and beyond.